INC. (NASDAQ:INCR) Files An 8-K Other Events
Item 8.01 – Other Events
On June 19, 2019, Innovus Pharmaceuticals, Inc., (the “Company”) issued a press release providing a business operations update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9 – Financial Statements and Exhibits
Item 9.01 Exhibits
INNOVUS PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 ex_147844.htm EXHIBIT 99.1 ex_147844.htm Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada -Company Also Updates on Additional Revenue-Generating Activity in that Country SAN DIEGO,…
To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
